Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 4, 2015, Pages 611-618

  Rogers, Toni Maree ^a   Russell, Prudence A ^b   Wright, Gavin ^c   Wainer, Zoe ^c   Pang, Jia Min ^a   Henricksen, Leigh A ^d   Singh, Shalini ^d   Stanislaw, Stacey ^d   Grille, James ^d   Roberts, Esteban ^d   Solomon, Benjamin ^a   Fox, Stephen B ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

ALK; Chromogenic in situ hybridization; Fluorescence in situ hybridization; Immunohistochemistry; Non small cell lung cancer; ROS1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CARCINOMA; CHROMOGENIC IN SITU HYBRIDIZATION; COMPARATIVE STUDY; CORRELATIONAL STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PATTERN RECOGNITION; PLEOMORPHIC CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROS1 GENE; TISSUE MICROARRAY; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; RETROSPECTIVE STUDY;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES;

EID: 84937700941     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000465     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, Global cancer statistics. CA Cancer J Clin 2011 61 69 90
2. Pao W, Miller VA, Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005 23 2556 2568
3. Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 350 2129 2139
4. Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 448 561 566
5. Rikova K, Guo A, Zeng Q, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007 131 1190 1203
6. Solomon B, Varella-Garcia M, Camidge DR, ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009 4 1450 1454
7. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA, The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010 46 1773 1780
8. Takeuchi K, Choi YL, Togashi Y, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009 15 3143 3149
9. Togashi Y, Soda M, Sakata S, KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012 7 e31323
10. Gu TL, Deng X, Huang F, Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011 6 e15640
11. Takeuchi K, Soda M, Togashi Y, RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012 18 378 381
12. Rimkunas VM, Crosby KE, Li D, Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: Identification of a FIG-ROS1 fusion. Clin Cancer Res 2012 18 4449 4457
13. Yoshida A, Tsuta K, Wakai S, Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 2014 27 711 720
14. García-Caballero T, Grabau D, Green AR, Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: A European multicentre study involving 168 specimens. Histopathology 2010 56 472 480
15. Gómez-Martin C, Garralda E, Echarri MJ, HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 2012 65 751 757
16. Schildhaus HU, Deml KF, Schmitz K, Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung. Mod Pathol 2013 26 1468 1477
17. Nitta H, Zhang W, Kelly BD, Automated brightfield break-Apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models. Methods 2010 52 352 358
18. Yoshida A, Tsuta K, Nitta H, Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-Associated protein-like 4-Anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011 6 1677 1686
19. Kim H, Yoo SB, Choe JY, Detection of ALK gene rearrangement in non-small cell lung cancer: A comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011 6 1359 1366
20. Selinger CI, Rogers TM, Russell PA, Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013 26 1545 1553
21. Travis WD, Brambilla E, Muller-Hermelink H.K., Harris CC, Pathology and Genetics: Tumours of the Lung, Pleua, Thymus and Heart. World Health Organisation Classification of tumours 2004 Lyon IARC Press
22. Travis WD, Brambilla E, Noguchi M, International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011 6 244 285
23. Kim HR, Lim SM, Kim HJ, The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 2013 24 2364 2370
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006 100 229 235
25. Bergethon K, Shaw AT, Ou SH, ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012 30 863 870
26. Sholl LM, Sun H, Butaney M, ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 2013 37 1441 1449
27. Warth A, Muley T, Dienemann H, ROS1 expression and translocations in non-small-cell lung cancer: Clinicopathological analysis of 1478 cases. Histopathology 2014 65 187 194
28. Yoshida A, Kohno T, Tsuta K, ROS1-rearranged lung cancer: A clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013 37 554 562
29. Shaw AT, Ou SH, Bang YJ, Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014 371 1963 1971
30. Sun JM, Choi YL, Won JK, A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 2012 7 e36 e38
31. Ren S, Hirsch FR, Varella-Garcia M, Atypical negative ALK break-Apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol 2014 9 e21 e23
32. Mahe E, Comment on 'testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization'. Mod Pathol 2014 27 1423 1424
33. Cooper WA, Solomon B, Response to Mahe. Mod Pathol 2014 27 1424 1425
34. Cabillic F, Gros A, Dugay F, Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 2014 9 295 306